Press release BoxID: 314870 (Evotec AG)
  • Evotec AG
  • Manfred Eigen Campus, Essener Bogen 7
  • 22419 Hamburg
  • Contact person
  • Jutta Fritz
  • +49 (89) 4613363-22

Kinaxo Extends its Collaboration with Roche

(PresseBox) (Martinsried, Germany, ) KINAXO Biotechnologies GmbH announced today that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.

KINAXO's phosphoproteomics platform PhosphoScout® enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using stateoftheart quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout® as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.

Evotec AG

KINAXO Biotechnologies is a privatelyheld biotechnology service company based in Munich/Martinsried, Germany. KINAXO offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug modeofaction analysis, cellular target profiling, target deconvolution, and drug repositioning.

KINAXO just completed a financing round and recently announced its collaboration with Bayer Vital GmbH for biomarker development, as well as renewing its ongoing agreement with Johnson & Johnson.